Her-2 overexpressed breast cancer may be resistant to endocrine therapy and some chemotherapies; however, it is sensitive to Herceptin treatment and exhibits more responsiveness to paclitaxel and anthracyclines [55]. This evidence concerns the gene ERBB2 and breast cancer.